The $156,000 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund research at Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to develop a novel therapeutic strategy for Alzheimer's disease (AD). The researchers aim to generate intrabodies to neutralize RNA::DNA hybrids that activate the cGAS-STING pathway, leading to neuroinflammation and neuronal death in AD cell models. Through this 2-year project, the researchers will validate the efficacy of the intrabodies in suppressing the cGAS-STING pathway in cerebral organoid models of sporadic and familial AD. This targeted approach seeks to address a key mechanism underlying the abnormal inflammatory response and cell death observed in AD, potentially leading to new precision medicine treatments to reduce neurodegeneration.
Generated 2/25/25, 5:13 AM